Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

corticosteroid

corticosteroid is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 18
News articles 0
Drug details — corticosteroid
Class
—
Route
—
Patents
20
Programs
18
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

corticosteroid is an FDA-listed pharmaceutical active ingredient.

Key facts

INN corticosteroid

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. AchilleS tendinoPathy treated with cortIcosteRoid injEctions. Phase 3 · Disc Medicine · Achilles tendinopathy
  2. 2G-MSC-GVHD Phase 2 · George Institute for · Patients who have developed acute GVHD refractory to cortico
  3. EAE140 Phase 2 · Createrna Science and · Primary Immune Thrombocytopenia
  4. IL-6 aGVHD Siltuximab: A phase II study to as... Phase 2 · Disc Medicine · Grade III/IV acute graft versus host disease of the liver of
  5. IVERMECTIN Phase 2 · George Institute for · Strongyloidiasis is caused by a parasite that is globally di
  6. corticosteroids Phase 2 · Chinese Academy of · Acute Severe Colitis (ASC)
  7. corticosteroids combined with immunoglobulin and romiplostim Phase 2 · Chinese Academy of · Primary Immune Thrombocytopenia
  8. AN OPEN-LABEL for Intramuscular administration of… Phase 1 · Anaxis Pharma · Intramuscular administration of triamcinolone acetonide Lisa

Related patents

Browse patents

  1. WO 2025125508

    COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ

    Expires Wed Jun 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2025068281

    CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES

    Expires Wed Mar 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. EP 4529925

    CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN

    Expires Tue Mar 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11464788

    Oligomer-corticosteroid conjugates

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11197822

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10456390

    Combinations comprising MABA compounds and corticosteroids

    Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10272037

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9782347

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9744126

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9511020

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. CA 2934118

    PROPIONATE DE CORTEXOLONE-17' DESTINE A ETRE UTILISE DANS LE TRAITEMENT DE LESIONS CUTANEES ET/OU DE TROUBLES DE LA PEAU ATROPHIQUE

    Expires Wed Jun 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8828980

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8796248

    Oligomer-corticosteroid conjugates

    Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8680082

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8680083

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8679545

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8658626

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Feb 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8653055

    Corticosteroid having low systemic absorption

    Expires Mon Feb 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8030297

    Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders

    Expires Mon Sep 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. AU 2005207635

    Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds

    Expires Wed Jul 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is corticosteroid?

corticosteroid is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.